Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2409399 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Cynthia E Dunbar. Beteiligte Einrichtung: From the Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, Genetic Therapy, Genetic Vectors, Lentivirus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
More than 30 years ago, the first transplantation with autologous hematopoietic stem cells modified with integrated murine retroviral vectors carrying potentially therapeutic genes was performed in patients with serious human disorders. The past decade has been marked by an acceleration in the publication of data from clinical trials and in regulatory approvals for therapies that use viral gene addition to treat hemoglobinopathies, immunodeficiencies, and metabolic neurologic disorders such as cerebral adrenoleukodystrophy. 1 After the induction of numerous hematologic cancers linked to activation or dysregulation of nearby oncogenes by viral promoter–enhancers contained within the retroviral vector among patients enrolled in early clinical . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Zitieren
APA
Dunbar, C. E. (2024). Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine. https://doi.org/10.1056/nejme2409399
Vancouver
Dunbar CE. Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine. 2024. doi:10.1056/nejme2409399
BibTeX
@article{Dunbar2024,
author = {Dunbar, Cynthia E},
title = {Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2409399}
}
EUVIMED